Sensyne issued shares at 175p as part of its initial public offering, and those shares are already trading at 187.5p – a gain of 7%
Sensyne Health PLC (LON:SENS) shares were in demand on Friday as the healthcare tech group made a solid start to life as an AIM-listed company.
The company, which uses artificial intelligence to develop medical products, issued shares at 175p as part of its initial public offering.
READ: Woodford will be hoping Sensyne can boost his flagging funds
Less than hour into its debut on the junior market, those shares are now trading at 187.5p – a 7% gain for the session so far.
“Today marks an important milestone for Sensyne Health,” said chief executive Paul Drayson.
“The strong support from institutional investors for our IPO will enable us to grow our team of highly skilled clinicians, data scientists and software developers to use the power of clinical AI to improve patient care and accelerate the development of new medicines.
He added: “Our evolution into a public company has already stimulated further business development interest in our work and we are delighted to begin life as a plc on the London Stock Exchange.
Drayson, a former Labour government minister, and his wife, founded the company and still hold a near-30% stake in the firm after the IPO, which valued Sensyne at £225mln.
View company profile